<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02213315</url>
  </required_header>
  <id_info>
    <org_study_id>D2190C00016</org_study_id>
    <nct_id>NCT02213315</nct_id>
  </id_info>
  <brief_title>A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Pharmacokinetics, Immunogenicity, and Safety of Mavrilimumab in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1 randomized, double blind single-dose study to evaluate the PK and immunogenicity of
      single SC 100 and 150 mg doses of mavrilimumab in healthy adult Japanese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled, parallel group, single-dose
      study to evaluate the PK, immunogenicity, and safety of mavrilimumab at doses of 100 and 150
      mg in healthy adult Japanese subjects. The study will be conducted at one site in Europe and
      subjects will be randomized in a 5:5:2 ratio to 100, 150mg mavrilimumab and placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK profile of mavrilimumab</measure>
    <time_frame>from dosing to day 85</time_frame>
    <description>•Non-compartmental PK parameters following a single-dose of mavrilimumab to analyse •Maximum observed concentration (Cmax); area under the concentration-time curve (AUC); time to maximum concentration (Tmax) and half-life (t1/2) from dosing to Day 85 •The number and percentage of subjects that are ADA positive will be summarized by dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of mavrilimumab</measure>
    <time_frame>from dosing to day 85</time_frame>
    <description>•The secondary outcome of the study is the safety of mavrilimumab as measured by the frequency and severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) from dosing to day 85</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>100mg arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150mg arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100mg Mavrilimumab</intervention_name>
    <description>100mg Mavrilimumab</description>
    <arm_group_label>100mg arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150mg mavrilimumab</intervention_name>
    <description>150mg mavrilmumab</description>
    <arm_group_label>150mg arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is of Japanese ethnicity

          -  No evidence of clinically significant respiratory disease

        Exclusion Criteria:

          -  Any condition that, would interfere with the evaluation of the study drug or safety of
             subjects.

          -  Subject has a known hypersensitivity to any components of the investigational product.

          -  History of infection requiring hospitalization or treatment with IV antibiotics within
             12 weeks before screening, or evidence of clinically significant active infection.

          -  Subject has a history or present condition of malignancy.

          -  Subject has a history or presence of drug addiction (urine test) or has alcohol
             consumption (breath test) of more than 21 (males) or 14 (females) units of alcohol per
             week.

          -  Any blood donation or significant loss of blood within 56 days of study initiation,

          -  Receipt of live (attenuated) vaccine within the 4 weeks before screening or during the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>malcolm Boyce, BSc MB ChB FRCP FFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Medicines Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2014</study_first_submitted>
  <study_first_submitted_qc>August 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2014</study_first_posted>
  <last_update_submitted>January 8, 2015</last_update_submitted>
  <last_update_submitted_qc>January 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers, Rheumatoid Arthritis, mavrilimumab</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

